Recent in vivo data have demonstrated a synergistic anti-tumor effect of SIRPα-specific antibodies in combination with tumor-opsonizing antibodies such as cetuximab (EGFR), rituximab (CD20), and trastuzumab human epidermal growth factor receptor (HER2) (25, 26, 29), and, currently, several anti-hSIRPα monoclonal antibodies including BI 765063 and GS-0189 (FIS-189) are in clinical trials for mono- and combination therapies (30). This evidence concerns the gene SIRPA and neoplasm.